Garadacimab API (CAS No. 2162134-62-3) is a fully human recombinant monoclonal antibody associated with hereditary angioedema (HAE) prophylaxis and advanced biologic pharmaceutical development.
Garadacimab is an IgG4 lambda monoclonal antibody designed to selectively target activated coagulation Factor XII, also known as Factor XIIa or FXIIa.
Activated Factor XII is an important initiator of the plasma contact system and kallikrein-kinin pathway. Activation of this pathway contributes to plasma kallikrein activity and bradykinin generation, which are closely associated with the vascular permeability and tissue swelling observed during hereditary angioedema attacks.
By binding to and inhibiting FXIIa, Garadacimab acts upstream in the HAE disease pathway and reduces activation of the kallikrein-kinin cascade.
Garadacimab is associated with prophylactic biologic products developed to prevent recurrent attacks of hereditary angioedema in adult and adolescent patients.
Pharmaceutical and biotechnology companies sourcing Garadacimab biological active substance commonly evaluate monoclonal antibody identity, protein purity, biological potency, FXIIa-binding activity, inhibitory activity, aggregate profile, charge variants, glycosylation characteristics, host cell proteins, residual host cell DNA, endotoxin, bioburden, and batch-to-batch consistency.
Because Garadacimab is a recombinant monoclonal antibody, control of higher-order protein structure, protein aggregation, post-translational modifications, charge heterogeneity, and biological activity is important during biologic API qualification.
Swapnroop Drugs and Pharmaceuticals supplies Garadacimab biological active material for qualified pharmaceutical research, monoclonal antibody development, analytical characterization, biologic development, and regulated pharmaceutical requirements with product-specific quality documentation and controlled supply-chain coordination.
Pharmaceutical and biotechnology companies evaluating Garadacimab biological active substance commonly focus on:
Target-binding activity and FXIIa inhibitory potency are important quality attributes during Garadacimab biological characterization.
Protein aggregation, charge heterogeneity, glycosylation characteristics, and process-related impurity control are also important during monoclonal antibody API development and qualification.
Garadacimab biological active material is primarily associated with:
Garadacimab-related pharmaceutical products are associated with prophylaxis to prevent hereditary angioedema attacks.
Garadacimab targets activated Factor XII, an upstream component of the plasma contact system.
Activation of FXII contributes to the kallikrein-kinin cascade, which ultimately promotes bradykinin generation.
Excessive bradykinin activity is associated with increased vascular permeability and swelling during hereditary angioedema attacks.
By inhibiting FXIIa, Garadacimab is designed to interfere with activation of the HAE pathway at an upstream stage.
Biotechnology companies evaluating Garadacimab biological material may review:
Product-specific quality specifications should be evaluated according to the intended biologic development program, analytical strategy, manufacturing process, and target regulatory market.
Garadacimab-related follow-on biologic development requires extensive analytical and biological characterization.
Important characterization parameters may include:
The exact regulatory requirements for biosimilar or follow-on biologic development depend on the target jurisdiction, reference product strategy, proposed manufacturing process, and applicable biologics regulations.
Swapnroop Drugs and Pharmaceuticals supports qualified pharmaceutical and biotechnology customers with:
Garadacimab biological active material is supplied in secure biologics-grade packaging selected according to protein concentration, material configuration, quantity, stability requirements, and approved product specification.
Product-appropriate primary containers and protective secondary packaging are selected according to the biological material configuration.
Temperature-controlled transportation and cold-chain logistics are coordinated according to product-specific storage and shipment requirements.
Development, analytical, and commercial quantities are coordinated according to availability, approved documentation, and customer requirements.
Packaging configuration, MOQ, supply quantity, temperature requirements, and shipment conditions are confirmed according to the applicable product specification and customer enquiry.
Store Garadacimab biological material under the controlled temperature conditions specified in the approved product documentation.
Protect the material from inappropriate temperature exposure, contamination, excessive agitation, and unsuitable environmental conditions.
Repeated freeze-thaw cycles should be avoided where restricted by the applicable product specification because inappropriate handling may influence protein aggregation and biological activity.
Handling should be performed by trained personnel according to approved monoclonal antibody and biological material handling procedures.
Product-specific storage and handling requirements should be confirmed from the approved COA, SDS, specification, and stability documentation.
Swapnroop Drugs and Pharmaceuticals provides Garadacimab biological active material supply and export coordination in India for qualified pharmaceutical companies, biotechnology organizations, monoclonal antibody researchers, analytical laboratories, rare disease drug developers, and biologics development customers.
For Garadacimab API price, CAS No. 2162134-62-3, protein purity, biological potency, FXIIa-binding activity, COA availability, MOQ, packaging configuration, temperature requirements, and export enquiries, contact our pharmaceutical sales team.
Get Bulk Quote via WhatsApp